文献速递妇科

卵巢癌中非BRCA1/2同源重组基因的致病性胚系变异:肿瘤表型与生存分析

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
PubMed 文献 · Gynecol Oncol · 2023-12-01

该研究纳入2015年7月1日至2020年12月31日接受肿瘤-正常测序的882例卵巢癌患者,评估非BRCA同源重组基因胚系致病性变异及其肿瘤表型和生存。6.3%患者携带非BRCA同源重组基因胚系致病变异,BRIP1、PALB2、RAD51B/C/D等基因双等位基因改变率高,PALB2和RAD51B/C/D相关肿瘤富集同源重组缺陷突变特征。仅BRCA1/2相关卵巢癌较野生型生存改善(p<0.01)。

要点

  • 882例卵巢癌中6.3%携带非BRCA同源重组基因胚系致病变异。
  • BRIP1、PALB2、RAD51B/C/D等基因双等位基因改变率高。
  • 仅BRCA1/2相关卵巢癌较野生型生存改善(p<0.01)。

核心结论

  • 非BRCA同源重组基因胚系致病变异相关卵巢癌为异质性群体,PALB2和RAD51B/C/D相关肿瘤呈现同源重组缺陷表型。

研究设计与样本

  • 研究纳入2015年7月1日至2020年12月31日接受肿瘤-正常测序(MSK-IMPACT)的卵巢癌患者882例,胚系评估BRCA1/2及其他同源重组基因ATM、BARD1、BRIP1、FANCA、FANCC、NBN、PALB2、RAD50、RAD51B、RAD51C和RAD51D。
  • 评估肿瘤内双等位基因失活,采用Kaplan-Meier法(左截断)从病理诊断计算无进展生存期和总生存期,部分患者行全外显子组测序。

主要发现

  • 882例卵巢癌中56例(6.3%)携带非BRCA同源重组基因胚系致病变异,95例(11%)为BRCA1相关卵巢癌(58例胚系、37例体细胞),59例(6.7%)为BRCA2相关卵巢癌(40例胚系、19例体细胞)。
  • 胚系致病变异中双等位基因改变率高:BRIP1为11/13、PALB2为3/4、RAD51B为3/4、RAD51C为3/4、RAD51D为8/10。
  • 行全外显子组测序的27/35例中,与BRIP1致病变异相比,PALB2和RAD51B/C/D胚系致病变异相关肿瘤的肿瘤突变负荷更高(中位数2.5 [1.1-6.0] vs. 1.2 mut/Mb [0.6-2.6])且同源重组缺陷突变特征富集(p<0.01)。
  • 端粒等位基因失衡和大规模状态转换等其他同源重组缺陷特征相似。
  • 尽管无进展生存期和总生存期在各基因组间存在异质性,仅BRCA1/2相关卵巢癌较野生型卵巢癌生存改善(p<0.01)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define molecular features of ovarian cancer (OC) with germline pathogenic variants (PVs) in non-BRCA homologous recombination (HR) genes and analyze survival compared to BRCA1/2 and wildtype (WT) OC. METHODS: We included patients with OC undergoing tumor-normal sequencing (MSK-IMPACT) from 07/01/2015-12/31/2020, including germline assessment of BRCA1/2 and other HR genes ATM, BARD1, BRIP1, FANCA, FANCC, NBN, PALB2, RAD50, RAD51B, RAD51C, and RAD51D. Biallelic inactivation was assessed within tumors. Progression-free (PFS) and overall survival (OS) were calculated from pathologic diagnosis using the Kaplan-Meier method with left truncation. Whole-exome sequencing (WES) was performed in a subset. RESULTS: Of 882 patients with OC, 56 (6.3%) had germline PVs in non-BRCA HR genes; 95 (11%) had BRCA1-associated OC (58 germline, 37 somatic); and 59 (6.7%) had BRCA2-associated OC (40 germline, 19 somatic). High rates of biallelic alterations were observed among germline PVs in BRIP1 (11/13), PALB2 (3/4), RAD51B (3/4), RAD51C (3/4), and RAD51D (8/10). In cases with WES (27/35), there was higher tumor mutational burden (TMB; median 2.5 [1.1-6.0] vs. 1.2 mut/Mb [0.6-2.6]) and enrichment of HR-deficient (HRD) mutational signatures in tumors associated with germline PALB2 and RAD51B/C/D compared with BRIP1 PVs (p < 0.01). Other features of HRD, including telomeric-allelic imbalance (TAI) and large-scale state transitions (LSTs), were similar. Although there was heterogeneity in PFS/OS by gene group, only BRCA1/2-associated OC had improved survival compared to WT OC (p < 0.01). CONCLUSIONS: OCs associated with germline PVs in non-BRCA HR genes represent a heterogenous group, with PALB2 and RAD51B/C/D associated with an HRD phenotype.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kahn RM, Selenica P, Boerner T, et al. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival. Gynecol Oncol. 2023. PMID: 38041901. doi:10.1016/j.ygyno.2023.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。